Research map: Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies

Back to the article

Papers in this map

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update · Josef S Smolen · 2017 · 7417 citations · Cited by this paper
  2. Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study) · 2026 · Related
  3. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force · Josef S Smolen · 2015 · 1485 citations · Cited by this paper
  4. Does Prior Exposure Affect Retention? A Real-World, Multicentre Assessment of IL-17 Inhibitor Cycling in Psoriatic Arthritis · 2026 · Related
  5. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. · David F Cella · 2005 · 507 citations · Cited by this paper
  6. Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study · 2026 · Related
  7. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study · Florence Tubach · 2012 · 430 citations · Cited by this paper
  8. Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials · 2025 · Related
  9. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy · Mark C. Genovese · 2019 · 336 citations · Cited by this paper
  10. Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies · 2026 · Related
  11. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial · Bernard G Combe · 2021 · 252 citations · Cited by this paper
  12. Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials · 2025 · Related
  13. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1) · René Westhovens · 2016 · 238 citations · Cited by this paper
  14. Long-term Effectiveness and Safety of Canakinumab in Patients with TRAPS: Analysis of the RELIANCE Non-Interventional Study · 2025 · Related
  15. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) · Arthur Kavanaugh · 2016 · 234 citations · Cited by this paper
  16. Real-World Effectiveness and Satisfaction with Risankizumab for the Treatment of Psoriatic Arthritis in Biologic-Naïve Patients: A Population Survey in the United States and Europe · 2025 · Related
  17. Patient Perceptions concerning Pain Management in the Treatment of Rheumatoid Arthritis · Peter Charles Taylor · 2010 · 182 citations · Cited by this paper
  18. Diuretic-Induced Hypomagnesemia May Play a Key Role in the Development of Calcium Pyrophosphate Arthritis · 2026 · Related
  19. Randomized controlled trials and real-world data: differences and similarities to untangle literature data · Sara M. Monti · 2018 · 168 citations · Cited by this paper
  20. Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials · 2025 · Related
  21. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. · Mark R. Kosinski · 2002 · 163 citations · Cited by this paper
  22. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial · René Westhovens · 2021 · 152 citations · Cited by this paper
  23. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration · Kim Lauper · 2022 · 150 citations · Cited by this paper
  24. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial · Peter Charles Taylor · 2019 · 94 citations · Cited by this paper
  25. Burden of rheumatoid arthritis on patients’ work productivity and quality of life · Ricardo Machado Xavier · 2019 · 87 citations · Cited by this paper
  26. A 5 item version of the Compliance Questionnaire for Rheumatology (CQR5) successfully identifies low adherence to DMARDs · Lyndsay Dawn Hughes · 2013 · 82 citations · Cited by this paper
  27. Real-world evidence research based on big data · Benedikt E. Maissenhaelter · 2018 · 79 citations · Cited by this paper
  28. Unraveling Patient‐Preferred Health and Treatment Outcomes in Early Rheumatoid Arthritis: A Longitudinal Qualitative Study · Kristien Van der Elst · 2015 · 70 citations · Cited by this paper
  29. Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. · Roberto Felice Caporali · 2019 · 62 citations · Cited by this paper
  30. Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis · George W Reed · 2019 · 47 citations · Cited by this paper
  31. Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies · Walter Reinisch · 2023 · 45 citations · Cited by this paper
  32. A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences · Nikos Maniadakis · 2018 · 43 citations · Cited by this paper
  33. A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience · Peter Charles Taylor · 2023 · 43 citations · Cited by this paper
  34. The Assessment of Fatigue in Rheumatoid Arthritis Patients and Its Impact on Their Quality of Life · Waseem Dar · 2022 · 40 citations · Cited by this paper
  35. The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life · Ian C. Scott · 2018 · 39 citations · Cited by this paper
  36. Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis · Eduardo Mysler · 2021 · 30 citations · Cited by this paper
  37. Conducting real-world evidence studies in India · Arun Bhatt · 2019 · 28 citations · Cited by this paper
  38. Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study) · Blanca Hernández‐Cruz · 2022 · 22 citations · Cited by this paper
  39. Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years · Gerd Rüdiger Burmester · 2024 · 19 citations · Cited by this paper

Source: OpenAlex (CC0)